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Abstract
Background: Although male predominance was documented in previous studies on cryptococcal meningoencephalitis
(CM), there has been no statistical study about female CM patients despite recently noticeable increase in female
prevalence. In the current study, we aimed to investigate the independent gender-specific contributing risk factors for
onset of CM and factors related to survival time in female patients by chosen statistical tools.
Methods: There have been 108 patients diagnosed with CM from July 1, 1998 to June 30, 2013 in Nanfang Hospital
that were included in our study. This 15-year retrospective study compared demographic and clinical features of 31
female patients with 77 males. Multivariate analysis was performed for detection of the contributors to the onset
of CM in female patients. The independent variables for multivariate analysis were selected according to statistical
significance in univariate analysis. Furthermore, Cox regression model was used to evaluate the factors related to
survival length.
Results: Use of corticosteroids or other immunosuppressants (32.3 % versus 11.7 %; p = 0.011) and history of
systemic lupus erythematosus (SLE) and other autoimmune diseases (29 % versus 3.9 %; p < 0.001) were more common
in females, but only the history of SLE or other autoimmune diseases was significant (OR 10.59, 95 % CI 1.49-74.77,
p = 0.02) by multivariate analysis. The ratio of cerebrospinal fluid (CSF) glucose-to-blood glucose was related to
the survival time (p = 0.03, 95 % CI 0-0.71).
Conclusions: The results showed that the history of SLE or other autoimmune diseases rather than chronic use
of corticosteroids and/or immunosuppressants was the independent gender-specific contributing risk factor in
female CM patients. Therefore, more attention should be made to the prevention of infection from the genus
Cryptococcus spp. in female patients with SLE or other autoimmune diseases. In addition, decreased ratio of CSF
glucose-to-blood glucose before antifungal therapy predicted the worse prognosis.
Keywords: Cryptococcal meningoencephalitis, Female, Gender-specific, Retrospective research, Contributing risk
factor, Survival length
* Correspondence: gzzhenghui0527@gmail.com; pansuyue82@qq.com
1Department of Neurology, Nanfang Hospital, Southern Medical University,
No.1838 North Guangzhou Avenue, Guangzhou City, Guangdong Province,
People’s Republic of China
Full list of author information is available at the end of the article
© 2016 Zheng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zheng et al. BMC Infectious Diseases  (2016) 16:22 
DOI 10.1186/s12879-016-1363-z
Background
The genus Cryptococcus spp. is an encapsulated yeast-like
fungus which causes life-threatening diseases and can in-
fect some important organs in the human body [1, 2]. Its
infection of the central nervous system (CNS)—crypto-
coccal meningoencephalitis (CM) - is one of the most
common fungal infection causing morbidity and mortality
worldwide [3, 4].
Many diseases have a different frequency and severity
between female and male [5, 6], a tendency featured in
CM. Male predominance was apparent in most of the
previous CM studies in different countries [1, 7–10], but
recently the noticeable increase in female prevalence
was seen, as suggested by the decreased male-to-female
ratio [10, 11]. Until now, several reports have called
attention to the female CM patients [12–16], but no
statistical study of these patients was found.
In the current study, by observing the gender differences
of the epidemiological characteristics, clinical features and
outcome in patients diagnosed with CM in Nanfang
Hospital in China, we firstly demonstrated the inde-
pendent gender-specific contributing risk factors for
the onset of CM and factors related to survival time in
female CM patients by chosen statistical tools.
Methods
Data source and study population
In this retrospective observational study, 108 patients
diagnosed with CM from Nanfang Hospital were in-
cluded between July 1, 1998 to June 30, 2013 (15 years).
Their medical records were reviewed to extract gender-
specific demographic and clinical features, including
potential risk factors, symptoms, cerebrospinal fluid
(CSF) analysis, electroencephalograph (EEG) and mag-
netic resonance imaging (MRI) results. Furthermore,
the probable contributing risk factors and survival time
of female CM patients were analyzed. All patients or
their family members signed a written consent in ac-
cordance with the ethical committee standards during
their hospital stay or outpatient follow-up and the writ-
ten approval for this study was obtained from the ethics
committee of the Nanfang Hospital.
Study criteria
CM was defined by either of the following criteria: (1)
isolation of the genus Cryptococcus spp. from previous
or current cerebrospinal fluid cultures, followed by a
positive CSF cryptococcal antibody, positive CSF India
ink staining, or positive CSF Aley new blue dye staining
and clinical features of meningoencephalitis; or (2) isola-
tion of the genus Cryptococcus spp. in blood culture with
clinical presentations of meningoencephalitis and typical
CSF features [17].
Patients were regarded as “with potential risk factors”
when they have HIV infection, malignancies, cirrhosis,
organ transplantation, end-stage renal failure autoimmune
disorder, diabetes mellitus, idiopathic CD4 T-cell lym-
phopenia, sarcoidosis, chronic usage of corticosteroids
or other immunosuppressive therapy [18], and systemic
lupus erythematosus (SLE) or other systemic autoimmune
diseases, chronic kidney diseases, pregnant, mycosis infec-
tion of other system, drug addiction, etc.
Bubble sign in MRI was diagnosed as follows [19]:
lesions frequently seen in the basal ganglia, thalami,
and midbrain, hyperintensity on T2-weighted images
and fluid attenuated inversion recovery (FLAIR) im-
ages without contrast enhancement.
Therapy
The 108 patients received treatment with an intravenous
administration of amphotericin B deoxycholate (AmBd),
which was given at 0.1 mg/kg the first day, 0.5 mg/kg
the second day and was increased to 1 mg/kg per day from
the third day, together with an oral 5-fluorocytosine (5-FC)
at 100 mg/kg per day and fluconazole (FCZ) at 400 mg per
day, once they were diagnosed with CM. After 4–6 weeks
of induction treatment, if the genus Cryptococcus spp. was
no longer present in at least three sequential CSF examina-
tions by microscopy, we stopped AmBd. We continued to
use FCZ and 5-FC for 6–9 more months. The patients with
persistent high intracranial pressure received a lumber
puncture every 2 or 3 days to relieve their symptoms.
Data analysis
For comparison of continuous variables, such as age,
CSF pressure, CSF protein, CSF glucose level, ratio of
CSF glucose-to-blood glucose, hospitalization length and
survival time, an independent sample t-test was performed.
Chi-square test was used to compare the categorical vari-
able, including bird/ bird dropping contact history, po-
tential risk factors, symptoms, EEGs, MRI results and
outcome status between female and male. Multivariate
analysis was performed for detection of the contributors
to the onset of CM in female patients. The independent
variables for multivariate analysis were selected according
to statistical significance in univariate analysis. Further-
more, Cox regression model was used to evaluate the
factors related to survival length. Statistical significance
was defined as p < 0.05 and data was analyzed using SPSS
16.0 software (SPSS, Chicago, IL, USA).
Results
Among the 108 CM patients collected from Nanfang
Hospital, 31 of them were female (Mean age33.55 ±
15.65 years old; Range 5–63 years old). Average time
interval from illness onset to hospitalization was 47.48 ±
82.42 days. Two cases had clear history of exposure to
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bird/bird droppings. There were 19 of 31 cases (61.3 %)
that had potential risk factors. The most common poten-
tial risk factor was chronic use of corticosteroids or other
immunosuppressants (10 cases, 32.3 %), and then SLE or
other autoimmune diseases (9 cases, 29.0 %), kidney dis-
eases (3 cases, 9.7 %), diabetes mellitus (1 case, 3.2 %),
tuberculosis (1 case, 3.23 %), hyperthyroidism (1 case,
3.23 %), pregnant (1 case, 3.23 %), hepatitis B infection
(1 case, 3.23 %) and gastric ulcer (1 case, 3.23 %)
(Table 1). Compared with male patients, the history of
SLE or other antoimmune diseases and the use of corti-
costeroids and/or other immunosuppressants had more
relationship to the onset of CM in female patients.
Nonspecific symptoms, such as headache (24 cases,
77.42 %) and fever (19 cases, 61.29 %) were frequently
found in female CM patients, while seizures (3 cases,
9.7 %), dizziness (1 case, 3.2 %), ataxia (1 case, 3.2 %)
and psychosis (2 cases, 6.5 %) were rare. Although female
were more inclined to visit a doctor because of uncon-
sciousness (25.8 % vs. 14.3 %), seizures (9.7 % vs. 6.5 %)
and dizziness (3.2 % vs. 1.3 %), there was no statistical dif-
ference (Table 2). In addition, there was no difference
between male and female in the first CSF results, contain-
ing CSF pressure, CSF glucose level, CSF protein, the ratio
of CSF glucose-to-blood glucose, EEG examinations, and
MRI results (Table 2).
There was no difference of hospitalization length
(53.35 ± 53.93 days vs. 50.71 ± 55.36 days, p = 0.44) and
survival time (21.22 ± 36.15 months vs. 30.40 ± 45.30
months, p = 0.09) between female and male CM pa-
tients. The mortality of female CM patients was slightly
higher (15 cases, 53.6 %) than male (30 cases, 45.5 %),
but without statistical significance (Table 2).
On our univariate analysis, use of corticosteroids and/
or immunosuppressants (32.3 % versus 11.7 %; p = 0.011)
and history of SLE or other autoimmune diseases (29 %
versus 3.9 %; p < 0.001) were significantly higher in female
CM patients. However, on multivariate analysis, we found
history of SLE or other autoimmune diseases was signifi-
cant between genders (odds ratio (OR) 10.59, 95 % confi-
dence interval (CI) 1.49-74.77, p = 0.02), while the use of
corticosteroids and/or immunosuppressants was not (OR
0.94, 95 % CI 0.18-4.86, p = 0.95) (Table 3).
Cox regression analysis of female CM patients demon-
strated that the decreased ratio of CSF glucose-to-blood
Table 1 Demographic characteristics, contact history and risk












Contact history, no. (%) 3 (3.9) 2 (1.4) 0.624
Risk factors
Use of corticosteroids and/or
immunosuppressants, no. (%)
9 (11.7) 10 (32.3) 0.011*
History of SLE or other
autoimmune diseases, no. (%)
3 (3.9) 9 (29) <0.001*
History of kidney diseasesa,
no. (%)
1 (1.3) 3 (9.7) 0.07
History of hematopathy, no. (%) 2 (2.6) 0 (0) 0.506
History of DM, no. (%) 4 (5.2) 1 (3.2) 0.554
History of TB, no. (%) 5 (6.5) 1 (3.2) 0.444
History of other diseasesb,
no. (%)
2 (2.6) 3 (9.7) 0.145
History of malignant cancer,
no. (%)
1 (1.3) 0 (0) 0.713
History of organ transplantation,
no. (%)
1 (1.3) 0 (0) 0.713
*P < 0.05
aKidney diseases included renal failure 2 cases and RPGN 1 case
bOther diseases included hyperthyroidism 1 case, pregnant 1 case and gastric
ulcer 1 case
Table 2 Clinical features and outcome related gender in CM
patients
Male (n = 77) Female (n = 31) P
Symptoms
Headache, no. (%) 57 (74.0) 24 (77.4) 0.713
Fever, no. (%) 48 (62.3) 19 (61.3) 0.919
Seizure, no. (%) 5 (6.5) 3 (9.7) 0.687
Dizziness, no. (%) 1 (1.3) 1 (3.2) 0.494
Ataxia, no. (%) 3 (3.9) 1 (3.2) 1
Unconsciousness, no. (%) 11 (14.3) 8 (25.8) 0.155
Psychosis, no. (%) 2 (2.6) 2 (6.5) 0.577
CSF, mean ± SD
Ratio of CSF glucose/Blood
glucose, mean ± SD
0.30 ± 0.18 0.28 ± 0.18 0.54
CSF pressure (mmH2O),
mean ± SD
266.49 ± 60.13 271.94 ± 49.49 0.66
CSF glucose (mmol/L),
mean ± SD
2.08 ± 1.36 1.64 ± 1.01 0.80
CSF protein (g/L),
mean ± SD
0.94 ± 1.53 0.86 ± 0.51 0.11
Abnormal EEGa, no. (%) 17 (68.0) 10 (76.9) 0.71
Abnormal MRIb, no. (%) 25 (75.8) 9 (60.0) 0.31
Outcome
Hospitalization length
(days), mean ± SD
50.71 ± 55.36 53.35 ± 53.93 0.44
Survival time (months),
mean ± SD
30.40 ± 45.30 21.22 ± 36.15 0.09
Dead, no. (%) 30 (45.5) 15 (53.6) 0.47
aAbnormal EEG included 5 cases had normal background with focal slow wave
and 5 had diffused slow wave in the background
bAbnormal MRI included Bubble sign 5 cases (2 at the basal ganglion and 3 at
subcortex), hydrocephalus 5 cases and 6 cases with abnormal cerebral lesions
(6 cases with more than one abnormal features)
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glucose was significantly related to survival time in fe-
male patients (p = 0.03, 95 % CI 0-0.71) while decreased
consciousness (p = 0.18, 95 % CI 0.07-1.65) and CSF
pressure (p = 0.41, 95 % CI 0.99-1.00) were not (Table 4).
Discussion
The genus Cryptococcus spp. can infect almost all organs
in the human body, but the site of serious consequence
is the central nervous system [2, 3]. Despite the im-
provements in diagnosis and management, lack of spe-
cific symptoms, long hospitalization and high mortality
still make CM a significant challenge to clinical works
[20, 21]. In this study, we compared the demographic
and clinical features of 31 female and 77 male CM pa-
tients, and attempted to analyze the independent risk
factor for onset of CM in female and the factors related
to their survival time.
The results of this study revealed several significant
features between female and male CM patients. In female
CM patients, use of corticosteroids and/or immunosup-
pressants and the history of SLE or other autoimmune
diseases were more common, but history of SLE or other
autoimmune diseases was the only clinical risk factor
independently contributed to the onset. Similar to our re-
sults from a previous study involving the whole popula-
tion [9], the ratio of CSF glucose-to-blood glucose was
the only factor related to the survival length of female
CM patients.
Kwon et al. [18] suggested several risk factors for CM
including HIV infection, malignancies, cirrhosis, organ
transplantation, end-stage renal failure autoimmune dis-
order, diabetes mellitus, idiopathic CD4 T-cell lympho-
penia, sarcoidosis, chronic usage of corticosteroids or
other immunosuppressive therapy. While Yuchong et al.
[3] found that tuberculosis and liver diseases were more
common potential risk factors in China. Additionally,
Guo et al. [22] suggested contact with birds/bird drop-
pings or saprophytes before illness onset in children. In
our study, the gender-specific risk factors in female CM
were use of corticosteroids and/or immunosuppressants
and the history of SLE or other autoimmune diseases.
This can probably be explained due to the marked gen-
der predilections with women more commonly afflicted
than men.
Surprisingly, the history of SLE or other autoimmune
diseases rather than the chronic use of corticosteroids and/
or immunosuppressants were the independent gender-
specific contributing risk factor to onset of CM in female
patients. Previous studies reported that efficient control of
cryptococcal infection requires a delicate balance of both
Th1- and Th2- type responses [23, 24]. It probably because
that T cells play a major role in SLE by amplifying the
autoimmune response leading to a misbalance of the
downstream cytokines [25], while the balance remains in
the inhibition of T-cell proliferation and activation caused
by use of corticosteroids and immunosuppressants.
This result demonstrated that once diagnosed with SLE
or other autoimmune diseases, the female patients should
be given prevention of the cryptococcal infection, inde-
pendent of chronic use of corticosteroids or other
immunosuppressants.
Decreased consciousness level, a lower CSF opening
pressure and the decreased ratio of CSF glucose-to-
blood glucose were reported contributed to CM prog-
nosis [26]. In our study, decreased ratio of CSF glucose-
to-blood glucose was the only factor related to the survival
length of female CM patients. This result illustrated that
the female CM patients who had decreased ratio of CSF
glucose-to-blood glucose in the first CSF analysis should
monitored closely during the therapy process, for they
may have longer hospitalization time and higher mortality.
This study had limitations inherent to all retrospective
studies, such as inconsistencies in patients care. Another
limitation results from lost contact with cases during the
follow-up process, particularly of cases in rural areas
where it is difficult to reach by mail, phone or car. One
of the strengths of our study is firstly demonstrating the
gender-specific risk factor for the onset of CM in female
patients as well as our use of Cox regression analysis to
assess the factors related to survival time in them.
Conclusions
The genus Cryptococcus spp. infection of CNS increased
in female patients in recent years. Use of corticosteroids
or other immunosuppressants and history of SLE and
other autoimmune diseases were more common in fe-
males than males. However, the history of SLE or other
Table 3 Multivariate conditional logistic analysis of independent
risk factors for onset of CM in female patients (n = 31)
Univariate analysis Multivariate analysis




2.23 1.27–3.93 0.011* 0.94 0.18–4.86 0.95
History of SLE or
other autoimmune
diseases
3.27 2.00–5.35 <0.001* 10.59 1.49–74.77 0.02*
*P < 0.05
Table 4 Cox regression analysis of risk factors for survival length
of female cryptococcal meningoencephalitis patients
Risk factors P OR 95 % CI
Decreased consciousness level 0.18 0.345 0.07–1.65
CSF pressure 0.41 0.996 0.99–1.00
The ratio of CSF glucose/ blood glucese 0.03* 0.018 0.00–0.71
*P < 0.05
Zheng et al. BMC Infectious Diseases  (2016) 16:22 Page 4 of 5
autoimmune diseases rather than chronic use of cortico-
steroids and/or immunosuppressants was the independent
gender-specific contributing risk factor to onset of CM in
female patients. Decreased ratio of CSF glucose-to-blood
glucose in the CSF analysis before antifungal therapy pre-
dicted the worse prognosis. So once diagnosed with SLE
or other autoimmune diseases, the female patients should
be given prevention of the cryptococcal infection, inde-
pendent of chronic use of corticosteroids or other immu-
nosuppressants. Furthermore the female patients who had
decreased ratio of CSF glucose-to-blood glucose in the
first CSF analysis should be monitored closely during the
therapy process.
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